Medical Oncology: A subspecialty of internal medicine concerned with the study of neoplasms.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Hematology: A subspecialty of internal medicine concerned with morphology, physiology, and pathology of the blood and blood-forming tissues.Cancer Care Facilities: Institutions specializing in the care of cancer patients.Societies, Medical: Societies whose membership is limited to physicians.Palliative Care: Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed)Oncology Nursing: A nursing specialty concerned with the care provided to cancer patients. It includes aspects of family functioning through education of both patient and family.Radiation Oncology: A subspecialty of medical oncology and radiology concerned with the radiotherapy of cancer.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Clinical Trials as Topic: Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.ItalyOncology Service, Hospital: The hospital department responsible for the administration and provision of diagnostic and therapeutic services for the cancer patient.Chemotherapy, Adjuvant: Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Questionnaires: Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Lung Neoplasms: Tumors or cancer of the LUNG.United StatesBreast Neoplasms: Tumors or cancer of the human BREAST.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Prostatic Neoplasms: Tumors or cancer of the PROSTATE.Urology: A surgical specialty concerned with the study, diagnosis, and treatment of diseases of the urinary tract in both sexes, and the genital tract in the male. Common urological problems include urinary obstruction, URINARY INCONTINENCE, infections, and UROGENITAL NEOPLASMS.Nuclear Physics: The study of the characteristics, behavior, and internal structures of the atomic nucleus and its interactions with other nuclei. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)Health Physics: The science concerned with problems of radiation protection relevant to reducing or preventing radiation exposure, and the effects of ionizing radiation on humans and their environment.Radiotherapy, Intensity-Modulated: CONFORMAL RADIOTHERAPY that combines several intensity-modulated beams to provide improved dose homogeneity and highly conformal dose distributions.Radiotherapy, Conformal: Radiotherapy where there is improved dose homogeneity within the tumor and reduced dosage to uninvolved structures. The precise shaping of dose distribution is achieved via the use of computer-controlled multileaf collimators.Radiotherapy Planning, Computer-Assisted: Computer-assisted mathematical calculations of beam angles, intensities of radiation, and duration of irradiation in radiotherapy.Radiotherapy Dosage: The total amount of radiation absorbed by tissues as a result of radiotherapy.Hospitals, Private: A class of hospitals that includes profit or not-for-profit hospitals that are controlled by a legal entity other than a government agency. (Hospital Administration Terminology, AHA, 2d ed)Hospitals: Institutions with an organized medical staff which provide medical care to patients.Hospitalization: The confinement of a patient in a hospital.Hospitals, Public: Hospitals controlled by various types of government, i.e., city, county, district, state or federal.Physician Executives: Physicians who serve in a medical and administrative capacity as head of an organized medical staff and who also may serve as liaison for the medical staff with the administration and governing board.SingaporeExploratory Behavior: The tendency to explore or investigate a novel environment. It is considered a motivation not clearly distinguishable from curiosity.Residential Facilities: Long-term care facilities which provide supervision and assistance in activities of daily living with medical and nursing services when required.Refusal to Treat: Refusal of the health professional to initiate or continue treatment of a patient or group of patients. The refusal can be based on any reason. The concept is differentiated from PATIENT REFUSAL OF TREATMENT see TREATMENT REFUSAL which originates with the patient and not the health professional.Breast: In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.GeorgiaHematologic Diseases: Disorders of the blood and blood forming tissues.Exopeptidases: A sub-class of PEPTIDE HYDROLASES that act only near the ends of polypeptide chains.Anemia, Sickle Cell: A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.Radiation Injuries: Harmful effects of non-experimental exposure to ionizing or non-ionizing radiation in VERTEBRATES.Radiation Dosage: The amount of radiation energy that is deposited in a unit mass of material, such as tissues of plants or animal. In RADIOTHERAPY, radiation dosage is expressed in gray units (Gy). In RADIOLOGIC HEALTH, the dosage is expressed by the product of absorbed dose (Gy) and quality factor (a function of linear energy transfer), and is called radiation dose equivalent in sievert units (Sv).Radiation, Ionizing: ELECTROMAGNETIC RADIATION or particle radiation (high energy ELEMENTARY PARTICLES) capable of directly or indirectly producing IONS in its passage through matter. The wavelengths of ionizing electromagnetic radiation are equal to or smaller than those of short (far) ultraviolet radiation and include gamma and X-rays.Dose-Response Relationship, Radiation: The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation.Radiation Tolerance: The ability of some cells or tissues to survive lethal doses of IONIZING RADIATION. Tolerance depends on the species, cell type, and physical and chemical variables, including RADIATION-PROTECTIVE AGENTS and RADIATION-SENSITIZING AGENTS.

Drug development in solid tumors: personal perspective of Dr. Emil J Freireich's contributions. (1/1614)

The development of chemotherapy for patients with the major cancers progressed from the initial success attained in the treatment of acute leukemias and choriocarcinoma. Many of the principles of therapy were based on the concepts developed in the experimental laboratories and early clinical studies done at the NIH Clinical Center and other centers around the country. The purpose of this review is to describe some of the early advances in cancer therapy and show how many are based on the efforts of Dr. Emil J Freireich. Over his career, Dr. Freireich has published more than 500 papers and worked on more than 70 different drugs and combinations. The principles defined by Dr. Freireich, namely, the use of intermittent intensive chemotherapy to induce complete remissions (CRs), intensification of therapy in remission, and the use of unmaintained remissions to assess cure, have been important in developing curative chemotherapy programs in patients with acute leukemias. These same principles were applied to combination therapy of Hodgkin's disease as the nitrogen mustard, vincristine, procarbazine, and prednisone combination was developed. This led to the high CR and cure rate for this disease. The treatment of metastatic breast cancer does not produce a high proportion of CRs, and cures of metastatic disease are unlikely with chemotherapy alone. But adjuvant chemotherapy after surgery has resulted in a significant reduction in cancer mortality. Many challenges remain in increasing the cure rate for the major solid tumors. New avenues of controlling cell growth and metastases need to be explored. One approach that is exploitable is the use of drugs or nutrients to prevent cancer. Laboratory approaches are now becoming a clinical reality.  (+info)

Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. (2/1614)

The purpose of this study was to review the progress in clinical and translational research in chronic myelogenous leukemia (CML) over the past 20 years at M.D. Anderson Cancer Center. The CML database updating the clinical and basic research investigations was reviewed as the source of this report. Publications resulting from these investigations were summarized. The long-term results with intensive chemotherapy, IFN-alpha therapy alone or in combination, autologous stem cell transplantation, and new agents such as homoharringtonine and decitabine showed encouraging results. Biological studies related to the BCR-ABL molecular abnormality, other molecular events, and the detection of minimal residual disease were detailed. Future strategies with potential promise in CML were outlined. Significant progress in understanding CML biology and in treating patients afflicted with the disease has occurred. Several therapeutic and research tools are currently investigated, which should hopefully improve further the prognosis of patients with CML.  (+info)

American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. (3/1614)

OBJECTIVE: To determine an effective, evidence-based, postoperative surveillance strategy for the detection and treatment of recurrent breast cancer. Tests are recommended only if they have an impact on the outcomes specified by American Society of Clinical Oncology (ASCO) for clinical practice guidelines. POTENTIAL INTERVENTION: All tests described in the literature for postoperative monitoring were considered. In addition, the data were critically evaluated to determine the optimal frequency of monitoring. OUTCOME: Outcomes of interest include overall and disease-free survival, quality of life, toxicity reduction, and secondarily cost-effectiveness. EVIDENCE: A search was performed to determine all relevant articles published over the past 20 years on the efficacy of surveillance testing for breast cancer recurrence. These publications comprised both retrospective and prospective studies. VALUES: Levels of evidence and guideline grades were rated by a standard process. More weight was given to studies that tested a hypothesis directly relating testing to one of the primary outcomes in a randomized design. BENEFITS, HARMS, AND COSTS: The possible consequences of false-positive and -negative tests were considered in evaluating a preference for one of two tests providing similar information. Cost alone was not a determining factor. RECOMMENDATIONS: The attached guidelines and text summarize the updated recommendations of the ASCO breast cancer expert panel. Data are sufficient to recommend monthly breast self-examination, annual mammography of the preserved and contralateral breast, and a careful history and physical examination every 3 to 6 months for 3 years, then every 6 to 12 months for 2 years, then annually. Data are not sufficient to recommend routine bone scans, chest radiographs, hematologic blood counts, tumor markers (carcinoembryonic antigen, cancer antigen [CA] 15-5, and CA 27.29), liver ultrasonograms, or computed tomography scans. VALIDATION: The recommendations of the breast cancer expert panel were evaluated and supported by the ASCO Health Services Research Committee reviewers and the ASCO Board of Directors.  (+info)

Follow-up of breast cancer in primary care vs specialist care: results of an economic evaluation. (4/1614)

A randomized controlled trial (RCT) comparing primary-care-centred follow-up of breast cancer patients with the current standard practice of specialist-centred follow-up showed no increase in delay in diagnosing recurrence, and no increase in anxiety or deterioration in health-related quality of life. An economic evaluation of the two schemes of follow-up was conducted concurrent with the RCT Because the RCT found no difference in the primary clinical outcomes, a cost minimization analysis was conducted. Process measures of the quality of care such as frequency and length of visits were superior in primary care. Costs to patients and to the health service were lower in primary care. There was no difference in total costs of diagnostic tests, with particular tests being performed more frequently in primary care than in specialist care. Data are provided on the average frequency and length of visits, and frequency of diagnostic testing for breast cancer patients during the follow-up period.  (+info)

Cancer carve outs, specialty networks, and disease management: a review of their evolution, effectiveness, and prognosis. (5/1614)

Specialty care programs for patients with cancer were among the first to be developed, yet they have been some of the slowest to grow or to demonstrate success. This paper reviews the evolution of cancer carve outs, disease management, and specialty networks by distinguishing purchasers from sellers on key attributes. It also describes financing and operational impediments to their growth and summarizes what little published data there is documenting the success of these programs. The paper analyzes the critical factors impeding the development of these cancer programs, and discusses the public policy changes and health services research that will need to be conducted before the performance and market influence of cancer carve outs will reach their full potential.  (+info)

Audiotapes and letters to patients: the practice and views of oncologists, surgeons and general practitioners. (6/1614)

A range of measures have been proposed to enhance the provision of information to cancer patients and randomized controlled trials have demonstrated their impact on patient satisfaction and recall. The current study explored the practice and views of oncologists, surgeons and general practitioners (GPs) with regards to providing patients with consultation audiotapes and summary letters. In stage 1, 28 semi-structured interviews with doctors were conducted to provide qualitative data on which to base a questionnaire. In stage 2, 113 medical oncologists, 43 radiation oncologists, 55 surgeons and 108 GPs completed questionnaires. Only one-third of doctors had ever provided patients with a copy of the letter written to the oncologist or referring doctor, and one-quarter had provided a summary letter or tape. The majority of doctors were opposed to such measures; however, a substantial minority were in favour of providing a letter or tape under certain conditions. More surgeons and GPs (> two-thirds) were opposed to specialists providing a consultation audiotape than oncologists (one-third). Gender, years of experience and attitude to patient involvement in decision-making were predictive of doctors' attitudes. The majority of doctors remain opposed to offering patients personalized information aids. However, practice and perspectives appear to be changing.  (+info)

Systematic review of cancer treatment programmes in remote and rural areas. (7/1614)

In an attempt to ensure high quality cancer treatment for all patients in the UK, care is being centralized in specialist centres and units. For patients in outlying areas, however, access problems may adversely affect treatment. In an attempt to assess alternative methods of delivering cancer care, this paper reviews published evidence about programmes that have set out to provide oncology services in remote and rural areas in order to identify evidence of effectiveness and problems. Keyword and textword searches of on-line databases (MEDLINE, EMBASE, HEALTHSTAR and CINAHL) from 1978 to 1997 and manual searches of references were conducted. Fifteen papers reported evaluations of oncology outreach programmes, tele-oncology programmes and rural hospital initiatives. All studies were small and only two were controlled, so evidence was suggestive rather than conclusive. There were some indications that shared outreach care was safe and could make specialist care more accessible to outlying patients. Tele-oncology, by which some consultations are conducted using televideo, may be an acceptable adjunct. Larger and more methodologically robust studies are justified and should be conducted.  (+info)

Improving the letters we write: an exploration of doctor-doctor communication in cancer care. (8/1614)

Referral and reply letters are common means by which doctors exchange information pertinent to patient care. Twenty-eight semi-structured interviews were conducted exploring the views of oncologists, referring surgeons and general practitioners. Twenty-seven categories of information in referral letters and 32 in reply letters after a consultation were defined. The letters to and from six medical oncologists relating to 20 consecutive new patients were copied, and their content analysed. Oncologists, surgeons and general practitioners Australia wide were surveyed using questionnaires developed on data obtained above. Only four of 27 categories of referral information appear regularly (in > 50%) in referral letters. Oncologists want most to receive information regarding the patient's medical status, the involvement of other doctors, and any special considerations. Referring surgeons and family doctors identified delay in receiving the consultant's reply letter as of greatest concern, and insufficient detail as relatively common problems. Reply letters include more information regarding patient history/background than the recipients would like. Referring surgeons and family doctors want information regarding the proposed treatment, expected outcomes, and any psychosocial concerns, yet these items are often omitted. Consultants and referring doctors need to review, and modify their letter writing practices.  (+info)

  • In conjunction with their medical oncology, radiation oncology, radiology, plastic and reconstructive surgery and pathology colleagues, the breast surgeons provide high quality multidisciplinary care at all three National Accreditation for Breast Cancers (NAPBC) accredited sites, a program administered by the American College of Surgeons. (
  • Attending physicians and fellows in medical oncology, diagnostic and therapeutic radiology, pathology and allied health care profesisonals from social services case management, nursing, dietary and physical therapy. (
  • The principles of oncology and therapeutic radiology are learned through carefully supervised evaluations of new patients emphasizing a holistic therapeutic approach. (
  • We convene regularly-scheduled site-specific tumor boards consisting of physicians from a variety of cancer specialties - such as medical, surgical and radiation oncology, pathology and radiology, as well as medical professionals in social work, dietary and other specialties - to provide a personalized treatment path. (
  • Members of Dr. Nsouli's team include Ryan S. Alden (4th year medical student at SUNY Upstate), Dr. William Ennis (Chief Resident), Dr. Michael Mix (faculty member), and Dr. Jeffrey Bogart (Chair, Dept. of Radiation Oncology, Interim Director of SUNY Upstate Cancer Center). (
  • Develop physician leaders in hematology and oncology by providing individualized training to fellows through strong mentorship, faculty supervision, and the opportunity to train on one of several different professional pathways. (
  • The Medical Oncology Track is ideal for fellows with a strong interest in an academic career in solid tumors and/or hematologic malignancies. (
  • The MSK Medical Oncology/Hematology Fellowship Training Program aims to provide fellows with comprehensive subspecialty training in clinical oncology while also developing their careers as future clinical and/or laboratory investigators. (
  • Learn more about the current Medical Oncology/Hematology fellows. (
  • In the first year of training, fellows are assigned to both inpatient and outpatient clinical rotations, with two-thirds of the first year of training exclusively set in mentored outpatient subspecialty care clinics During outpatient blocks, fellows spend time in a variety of subspecialty clinics to maximize exposure in both medical oncology and hematology. (
  • The Medical Oncology Division is dedicated to teaching our science to the public, patients, medical students, residents and fellows. (
  • The wide variety of Hematology and Oncology clinics at Boston Medical Center provide a rich resource for learning and the program places great emphasis on making the most of these resources for satisfying and stimulating training for Fellows. (
  • Ideally, Fellows will attend clinics at the hospital center at which they are doing their inpatient rotations (e.g. if they are assigned to Boston Medical Center they will do all clinics there). (
  • Having certain Attendings identified with specific Hematology or Oncology problems also makes it easy for Fellows and primary care doctors to know who to call for information and follow up of new patients with specific diseases. (
  • While at Boston Medical Center the Fellows will be assigned to attend certain of these clinics for at least 6 months during the first two years of training. (
  • As a member of the Children's Oncology Group (COG), Rush offers our pediatric and young adult patients opportunities to enroll in National Cancer Institute-backed clinical trials of new treatments for pediatric cancers, including sarcomas (bone cancer) , brain tumors , leukemia and lymphoma. (
  • Oncology is the branch of medicine dealing with tumors (cancer). (
  • The Veterinary Medical Center at The Ohio State University is one of only a few places in North America to offer evaluation and comprehensive treatment of tumors in horses. (
  • Working within the thoracic oncology program, Gettinger treats a variety of cancers that originate in the thoracic cavity, such as chest wall tumors, lung cancer, mediastinal tumors, thymomas and malignant mesothelioma. (
  • ESMO Asia 2018 will keep oncology professionals in the Asia-Paci﫿c region up to date with the fast pace of oncology science and education, and provide important networking opportunities with international peers. (
  • The ESMO membership booth will be at several oncology meetings in 2018. (
  • Oncology is the study of a variety of tumours, namely the various cancers that can affect a human being. (
  • The comprehensive thoracic oncology program at Virginia Mason is dedicated to achieving superior outcomes for patients with cancers of the lung, esophagus and other areas of the chest. (
  • The Radiation Oncology Department uses the most advanced technologies available to treat a wide range of cancers along with selected noncancerous conditions. (
  • The Medical Oncology Division specializes in the treatment of solid tumor cancers and research dedicated to improving therapy of solid tumor cancers which include but are not limited to genitourinary, breast, head and neck, thyroid, and lung. (
  • With the majority of cancers occurring in individuals over the age of 65 against a backdrop of an expanding aging population, there is an urgent need to integrate the areas of clinical oncology and geriatric care. (
  • Many hospitals are developing an oncology service structure that has the potential to improve clinical and financial performance, encourage physician engagement, create a distinct brand in the market, and gain a competitive edge. (
  • Dr Anne Rigg was appointed as a consultant in medical oncology at Guy's and St Thomas' Hospitals in 2005, after completing clinical and academic training at the Royal Marsden Hospital and Imperial College. (
  • Six hospitals in the north of England are implementing a Varian Medical Systems software system that enables them to function as one clinical network. (
  • The rollout of ARIA for Medical Oncology at hospitals in Lancashire and Cumbria is expected to improve patient care and departmental efficiency by fully integrating the prescribing, preparation, dispensing and administration of drugs for treating cancer. (
  • Varian's medical oncology solution is already in place in several UK hospitals, including in London (St Barts), Norwich, Stoke, Truro and Romford, and is now being implemented across a number of other cancer networks. (
  • The Program is a one year certificate program based at UNC Hospitals' Department of Radiation Oncology in Chapel Hill, NC. (
  • Around 176,000 of those issues go out to home subscribers, with the rest going to oncology offices, infusion rooms, nonprofits, hospitals and academic groups. (
  • Tufts Medical Center is a proud member of Wellforce , a health system in Massachusetts focused on supporting clinicians and helping them focus on what they do best: care for people. (
  • Froedtert Hospital and The Medical College of Wisconsin's Breast Surgery Program was one of the first well-established cancer programs in the institution and has served as the model for other disease-specific, multidisciplinary cancer programs. (
  • This timely work tackles these issues head-on, presenting a truly multidisciplinary and international perspective on cancer and aging from world-renowned experts in geriatrics, oncology, behavioral science, psychology, gerontology, and public health. (
  • The advantage of having clinics which focus on particular disease types within Hematology and Oncology is that such clinics are more easily adapted to the multidisciplinary approach. (
  • This group studies the biology of myeloma and lymphoma in collaboration with the Divisions of Clinical Hematology, the Division of Experimental Oncology and Cell Biology. (
  • Currently, as professor in the field of Experimental Oncology at the department of Medical Oncology, UMCG, Groningen, his group is continuing work on targeting cell death regulatory mechanisms and stress responses in cancer. (
  • Associate PD Group Medical Directors participate in the development of, and make contributions to, in the assigned therapeutic area's scientific and clinical strategies and plans. (
  • The B-Cell Lymphoma Moon Shot is revolutionizing the conventional medical research approach to rapidly translate findings into patient treatment options and develop personalized therapeutic strategies. (
  • The department of Medical Oncology works on the identification and characterization of novel therapeutic targets, the development of better imaging strategies and molecular biomarkers for tumor detection and patient monitoring. (
  • Innovation has been a long-standing strength of the Therapeutic Medical Physics Division, exemplified by our pioneering work in image-based treatment planning systems during the 1980's (PLanUNC), and today, in the development of nanotechnology-based radiation research technology. (
  • Welcome to the webpage of the Division of Therapeutic Medical Physics. (
  • Dr. Kaoutar Tlemcani, MD is a medical oncology doctor who practices in Zion, IL. (
  • Dr. Coralia Calomini, MD is a medical oncology doctor who practices in Bend, OR. (
  • Likewise, the OMH model has been developed as a mechanism to hold oncology practices accountable for meeting the standards that ensure quality, comprehensive care, and decreased variation. (
  • Four unique medical practices were evaluated by users and those in a current implementation process on their satisfaction levels per vendor. (
  • Intrigued by cancer biology and therapy he entered the field of oncology, exploring the possibility of using the FA pathway and apoptosis as targets for cancer therapy at the department of Medical Oncology at the VUMC, Amsterdam, the Netherlands. (
Graduate handbooks | University of Oxford
Graduate handbooks | University of Oxford (
Oncologist Jobs in Phoenix, AZ |
Oncologist Jobs in Phoenix, AZ | (
European Medical Journal Oncology | Directory of Open Access Journals
European Medical Journal Oncology | Directory of Open Access Journals (
Liver Cancer Treatment Program
Liver Cancer Treatment Program (
Breast Cancer Survivorship: Johns Hopkins Kimmel Cancer Center
Breast Cancer Survivorship: Johns Hopkins Kimmel Cancer Center (
Melanoma Disease-Oriented Team: Simmons Cancer Center - UT Southwestern, Dallas, Texas
Melanoma Disease-Oriented Team: Simmons Cancer Center - UT Southwestern, Dallas, Texas (
Personal tales of survivorship | MD Anderson Cancer Center
Personal tales of survivorship | MD Anderson Cancer Center (
Community Academic Profiles - Faculty & Researchers - Stanford Medicine
Community Academic Profiles - Faculty & Researchers - Stanford Medicine (
Lymphazurin  - Side effect(s)
Lymphazurin - Side effect(s) (
Norethindrone Acetate and Ethinyl Estradiol Drug Information - Indications, Dosage, Side Effects and Precautions
Norethindrone Acetate and Ethinyl Estradiol Drug Information - Indications, Dosage, Side Effects and Precautions (
Meet the Pancreas and Liver Team | BIDMC of Boston
Meet the Pancreas and Liver Team | BIDMC of Boston (
David J. Kwiatkowski, MD, PhD - Dana-Farber Cancer Institute | Boston, MA
David J. Kwiatkowski, MD, PhD - Dana-Farber Cancer Institute | Boston, MA (
Dexrazoxane Drug Information - Indications, Dosage, Side Effects and Precautions
Dexrazoxane Drug Information - Indications, Dosage, Side Effects and Precautions (
Robert J. Soiffer, MD - Dana-Farber Cancer Institute | Boston, MA
Robert J. Soiffer, MD - Dana-Farber Cancer Institute | Boston, MA (
Philip J. Gold, M.D. | Seattle, WA
Philip J. Gold, M.D. | Seattle, WA (
George D. Demetri, MD - Dana-Farber Cancer Institute | Boston, MA
George D. Demetri, MD - Dana-Farber Cancer Institute | Boston, MA (
Top Doctors 2011: The List - 5280
Top Doctors 2011: The List - 5280 (
Pentazocine Drug Information - Indications, Dosage, Side Effects and Precautions
Pentazocine Drug Information - Indications, Dosage, Side Effects and Precautions (
How to Take Alvimopan Capsules and Dose of Alvimopan Capsules| Medindia
How to Take Alvimopan Capsules and Dose of Alvimopan Capsules| Medindia (
Crotalidae Polyvalent Immune Fab Ovine - Side effect(s)
Crotalidae Polyvalent Immune Fab Ovine - Side effect(s) (
Geoffrey R. Oxnard, MD - Dana-Farber Cancer Institute | Boston, MA
Geoffrey R. Oxnard, MD - Dana-Farber Cancer Institute | Boston, MA (